OBJECTIVE: Multiple myeloma (MM) comprises 1% of all cancers and 10% of hematologic malignancies and known as an incurable disease. The introduction of immunomodulatory drugs (IMiDs) has brought a major shift in therapeutic paradigm in the treatment of newly diagnosed and relapsed/refractory MM patients. The aim of this study was to evaluate the relationship between response status and hematological parameters in patients with MM treated with thalidomide or lenalidomide. METHODS: Sixty-eight patients who were treated with IMiDs in Ege University, School of Medicine, Department of Hematology, between 2005 and 2012, were evaluated, retrospectively. RESULTS AND CONCLUSION: We could not find any difference between the hematological parameters before and after the treatment neither with thalidomide nor lenalidomide. However, the heterogenity of our groups, the difference in treatment strategies and potential side effects would have an impact on this result. It is needed to perform prospective clinical trials to prove that whether correction of hematological parameters would reflect the response status in patients with myeloma that treated with IMiDs.
OBJECTIVE:Multiple myeloma (MM) comprises 1% of all cancers and 10% of hematologic malignancies and known as an incurable disease. The introduction of immunomodulatory drugs (IMiDs) has brought a major shift in therapeutic paradigm in the treatment of newly diagnosed and relapsed/refractory MM patients. The aim of this study was to evaluate the relationship between response status and hematological parameters in patients with MM treated with thalidomide or lenalidomide. METHODS: Sixty-eight patients who were treated with IMiDs in Ege University, School of Medicine, Department of Hematology, between 2005 and 2012, were evaluated, retrospectively. RESULTS AND CONCLUSION: We could not find any difference between the hematological parameters before and after the treatment neither with thalidomide nor lenalidomide. However, the heterogenity of our groups, the difference in treatment strategies and potential side effects would have an impact on this result. It is needed to perform prospective clinical trials to prove that whether correction of hematological parameters would reflect the response status in patients with myeloma that treated with IMiDs.
Authors: Anders Waage; Peter Gimsing; Gunnar Juliusson; Ingemar Turesson; Nina Gulbrandsen; Tommy Eriksson; Martin Hjorth; Johan Lanng Nielsen; Stig Lenhoff; Jan Westin; Finn Wislöff Journal: Br J Haematol Date: 2004-04 Impact factor: 6.998
Authors: S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie Journal: N Engl J Med Date: 1999-11-18 Impact factor: 91.245
Authors: T Hideshima; D Chauhan; Y Shima; N Raje; F E Davies; Y T Tai; S P Treon; B Lin; R L Schlossman; P Richardson; G Muller; D I Stirling; K C Anderson Journal: Blood Date: 2000-11-01 Impact factor: 22.113
Authors: Francesca Gay; Suzanne R Hayman; Martha Q Lacy; Francis Buadi; Morie A Gertz; Shaji Kumar; Angela Dispenzieri; Joseph R Mikhael; P Leif Bergsagel; David Dingli; Craig B Reeder; John A Lust; Stephen J Russell; Vivek Roy; Steven R Zeldenrust; Thomas E Witzig; Rafael Fonseca; Robert A Kyle; Philip R Greipp; A Keith Stewart; S Vincent Rajkumar Journal: Blood Date: 2009-12-11 Impact factor: 22.113
Authors: Divaya Bhutani; Jeffrey Zonder; Jason Valent; Nishant Tageja; Lois Ayash; Abhinav Deol; Zaid Al-Kadhimi; Judith Abrams; Lawrence Lum; Voravit Ratanatharathorn; Joseph Uberti; Muneer H Abidi Journal: Support Care Cancer Date: 2013-04-17 Impact factor: 3.603
Authors: Monika Engelhardt; Evangelos Terpos; Martina Kleber; Francesca Gay; Ralph Wäsch; Gareth Morgan; Michele Cavo; Niels van de Donk; Andreas Beilhack; Benedetto Bruno; Hans Erik Johnsen; Roman Hajek; Christoph Driessen; Heinz Ludwig; Meral Beksac; Mario Boccadoro; Christian Straka; Sara Brighen; Martin Gramatzki; Alessandra Larocca; Henk Lokhorst; Valeria Magarotto; Fortunato Morabito; Meletios A Dimopoulos; Hermann Einsele; Pieter Sonneveld; Antonio Palumbo Journal: Haematologica Date: 2014-02 Impact factor: 9.941
Authors: Gaber El-Saber Batiha; Mohammed Alqarni; Dina A B Awad; Abdelazeem M Algammal; Richard Nyamota; Mir I I Wahed; Muhammad Ajmal Shah; Mohammad N Amin; Babatunde O Adetuyi; Helal F Hetta; Natália Cruz-Martins; Niranjan Koirala; Arabinda Ghosh; Javier Echeverría; Jorge Pamplona Pagnossa; Jean-Marc Sabatier Journal: Front Nutr Date: 2021-07-12